Drugs / F-18 FEDAA1106
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01031199 | Jan → Dec 2009 | multiple sclerosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01035164 | Jun 2007 → Jan 2010 | Alzheimer disease | Bayer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 FEDAA1106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01031199 ↗ |
| Known as | 18F-FEDAA1106 | “Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 250 MBq (6.75 mCi) ZK 6032924 (18F-FEDAA1106)” NCT01035164 ↗1“[18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO.” PMID 23618062 ↗ Apr 2013 |
| Known as | BAY85-8101 | “F-18 FEDAA1106 (BAY85-8101)” NCT01031199 ↗ |
| Modality | Diagnostic / imaging agent | “[18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO.” PMID 23618062 ↗ Apr 2013 |
| Target | TSPO | “[18F]FEDAA1106 is a recently developed PET radioligand for the in vivo quantification of TSPO.” PMID 23618062 ↗ Apr 2013 |